CHO Plus
Early-stage biotechnology company developing a directed-evolution cell engineering platform to create mammalian host cell lines with substantially increased productivity for therapeutic proteins and viral vectors. The organization demonstrates cell engineering, clone screening, and analytical workflows to produce and characterize high‑productivity CHO and HEK-293 derived cell lines for monoclonal antibody and AAV manufacturing, and pursues commercialization via licensing and collaborations.
Industries
Nr. of Employees
small (1-50)
Patents
Cell hybrids as virus packaging cells for high efficiency production of gene therapy vectors and viral vaccines
US-12252713-B2
View Details
Cell hybrids as virus packaging cells for high efficiency production of gene therapy vectors and viral vaccines
US-12252713-B2
View DetailsProducts
Engineered CHO host cell lines for mAb production
Mammalian host cell lines engineered for increased endoplasmic reticulum capacity and higher specific productivity, demonstrated at shake-flask fed-batch scale with increased volumetric titers and multi‑generation stability.
Engineered HEK-293 host cell lines and producer cell lines for AAV
Engineered HEK-293 suspension hosts and stable producer cell lines selected for higher AAV capsid titers, increased percent-full capsids, and improved functional titers across multiple serotypes.
Engineered CHO host cell lines for mAb production
Mammalian host cell lines engineered for increased endoplasmic reticulum capacity and higher specific productivity, demonstrated at shake-flask fed-batch scale with increased volumetric titers and multi‑generation stability.
Engineered HEK-293 host cell lines and producer cell lines for AAV
Engineered HEK-293 suspension hosts and stable producer cell lines selected for higher AAV capsid titers, increased percent-full capsids, and improved functional titers across multiple serotypes.
Services
Development of engineered mammalian host cell lines for increased protein or viral vector productivity and licensing of cell line technology to biopharmaceutical manufacturers.
Creation and characterization of stably transfected producer cell lines for viral vector production with improved titer and capsid quality attributes.
Development of engineered mammalian host cell lines for increased protein or viral vector productivity and licensing of cell line technology to biopharmaceutical manufacturers.
Creation and characterization of stably transfected producer cell lines for viral vector production with improved titer and capsid quality attributes.
Expertise Areas
- Cell line engineering for biologics
- Directed evolution and genome shuffling
- Monoclonal antibody production (CHO-based)
- AAV vector production (HEK-293 based)
Key Technologies
- Homotypic cell fusion and genome shuffling
- Directed evolution of mammalian hosts
- Flow cytometry and fluorescence-based screening
- Transposase-mediated stable integration
News & Updates
Announcement of a U.S. patent covering improved production of viral vectors for gene therapy.
Entered into a project agreement to develop high-productivity cell lines for filovirus monoclonal antibody production.
Announcement of U.S. patent related to improved production of proteins using engineered yeast cells.
Selected for an accelerator program for biomanufacturing technology developers.
U.S. patent issued covering cell lines for high-level production of protein-based pharmaceuticals (US 10,329,594).
Announcement of a U.S. patent covering improved production of viral vectors for gene therapy.
Entered into a project agreement to develop high-productivity cell lines for filovirus monoclonal antibody production.
Announcement of U.S. patent related to improved production of proteins using engineered yeast cells.
Selected for an accelerator program for biomanufacturing technology developers.
U.S. patent issued covering cell lines for high-level production of protein-based pharmaceuticals (US 10,329,594).